Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP Parkinsonian mice

Neurotoxicity Research

Volumn 17, Issue 2, 2010, Pages 142-155

  Deguil, Julie ^a   Chavant, François ^a,b   Lafay Chebassier, Claire ^b   Pérault Pochat, Marie Christine ^a,b   Fauconneau, Bernard ^a,b   Pain, Stéphanie ^a,b  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Memory task; Mice; MPTP; Neuroprotection; PACAP27; Parkinson; Translational control

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE R; TYROSINE 3 MONOOXYGENASE; G PROTEIN COUPLED RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPROTECTIVE AGENT; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; C57BL 6 MOUSE; CELL LOSS; CHEMICAL ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FRONTAL CORTEX; GENETIC DISORDER; HIPPOCAMPUS; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MENTAL DETERIORATION; MENTAL TASK; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS REGULATION; SPATIAL MEMORY; TRANSLATION INITIATION; TREATMENT DURATION; WORKING MEMORY; ANIMAL; ASSOCIATION; C57BL MOUSE; CELL COUNT; COGNITION; DEPTH PERCEPTION; DISEASE MODEL; DRUG INTERACTION; GENE EXPRESSION REGULATION; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; MEMORY; METABOLISM; METHODOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; VISION;

MUS; PARKINSONIA;

ANIMALS; CELL COUNT; COGNITION; COGNITION DISORDERS; CUES; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; INJECTIONS, INTRAVENOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SPACE PERCEPTION; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VISUAL PERCEPTION;

EID: 77449090243     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9091-4     Document Type: Article

References (72)

1. Arimura A, Somogyvari-Vigh A, Weill C, Fiore RC, Tatsuno I, Bay V, Brenneman DE (1994) PACAP functions as a neurotrophic factor. Ann NY Acad Sci 739:228-243
2. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN (1998) Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 17:6888-6902
3. Bando Y, Onuki R, Katayama T, Manabe T, Kudo T, Taira K, Tohyama M (2005) Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease. Neurochem Int 46:11-18
4. Banks WA, Uchida D, Arimura A, Somogyvari-Vigh A, Shioda S (1996) Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Ann NY Acad Sci 805:270-277; discussion 277-279
5. Bobrovskaya L, Gelain DP, Gilligan C, Dickson PW, Dunkley PR (2007) PACAP stimulates the sustained phosphorylation of tyrosine hydroxylase at serine 40. Cell Signal 19:1141-1149
6. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205:929-932
7. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO (2004) Hippocampal and prefrontal atrophy in patients with early nondemented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 75:1467-1469
8. Bubser M, Schmidt WJ (1990) 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav Brain Res 37:157-168
9. Cammalleri M, Lutjens R, Berton F, King AR, Simpson C, Francesconi W, Sanna PP (2003) Time-restricted role for dendritic activation of the mTOR-p70S6 K pathway in the induction of late-phase long-term potentiation in the CA1. Proc Natl Acad Sci USA 100:14368-14373
10. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14:1709-1725
11. Clemens MJ (2001) Translational regulation in cell stress and apoptosis. Roles of the eIF4E binding proteins. J Cell Mol Med 5:221-239
12. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 115(Pt 6):1701-1725
13. Costa-Mattioli M, Gobert D, Harding H, Herdy B, Azzi M, Bruno M, Bidinosti M, Ben Mamou C, Marcinkiewicz E, Yoshida M, Imataka H, Cuello AC, Seidah N, Sossin W, Lacaille JC, Ron D, Nader K, Sonenberg N (2005) Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature 436:1166-1173
14. Costa-Mattioli M, Gobert D, Stern E, Gamache K, Colina R, Cuello C, Sossin W, Kaufman R, Pelletier J, Rosenblum K, Krnjevic K, Lacaille JC, Nader K, Sonenberg N (2007) eIF2alpha phosphorylation bidirectionally regulates the switch from short- to longterm synaptic plasticity and memory. Cell 129:195-206
15. Da Cunha C, Angelucci ME, Canteras NS, Wonnacott S, Takahashi RN (2002) The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol 22:227-237
16. Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS (2001) Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 124: 9-18
17. Da Cunha C, Wietzikoski S, Wietzikoski EC, Miyoshi E, Ferro MM, Anselmo-Franci JA, Canteras NS (2003) Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system. Neurobiol Learn Mem 79:236-242
18. Deguil J, Jailloux D, Page G, Fauconneau B, Houeto JL, Philippe M, Muller JM, Pain S (2007) Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP? -induced alteration of translational control in Neuro-2a neuroblastoma cells. J Neurosci Res 85:2017-2025
19. Der SD, Yang YL, Weissmann C, Williams BR (1997) A doublestranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA 94:3279-3283
20. Dogrukol-Ak D, Tore F, Tuncel N (2004) Passage of VIP/PACAP/ secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 10:1325-1340
21. Dubois B, Pillon B (1997) Cognitive deficits in Parkinson's disease. J Neurol 244:2-8
22. Dufner A, Thomas G (1999) Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 253:100-109
23. Farkas O, Tamas A, Zsombok A, Reglodi D, Pal J, Buki A, Lengvari I, Povlishock JT, Doczi T (2004) Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury. Regul Pept 123:69-75
24. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C (2005) Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 148:78-87
25. Frick KM, Baxter MG, Markowska AL, Olton DS, Price DL (1995) Age-related spatial reference and working memory deficits assessed in the water maze. Neurobiol Aging 16:149-160
26. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041
27. Gerlach M, Double KL, Youdim MB, Riederer P (2000) Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotox Res 2:99-114
28. Gevaerd MS, Miyoshi E, Silveira R, Canteras NS, Takahashi RN, Da Cunha C (2001) L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. Int J Neuropsychopharmacol 4:361-370
29. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15:2852-2864
30. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97:2875-2880
31. Kesner RP (2000) Behavioral analysis of the contribution of the hippocampus and parietal cortex to the processing of information: interactions and dissociations. Hippocampus 10:483-490
32. Kostrzewa RM, Segura-Aguilar J (2002) Neurotoxicological and neuroprotective elements in Parkinson's disease. Neurotox Res 4:83-86
33. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, Pradier L, Hugon J (2005) mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem 94:215-225
34. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM (1992) L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 107:394-404
35. Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson's disease. Brain 106(Pt 2):257-270
36. Levin BE, Llabre MM, Weiner WJ (1989) Cognitive impairments associated with early Parkinson's disease. Neurology 39:557-561
37. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM (2003) Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 23:6351-6356
38. Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA (2006) RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci 26:9996-10005
39. Masuo Y, Matsumoto Y, Tokito F, Tsuda M, Fujino M (1993) Effects of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) on the spontaneous release of acetylcholine from the rat hippocampus by brain microdialysis. Brain Res 611:207-215
40. Miyoshi E, Wietzikoski S, Camplessei M, Silveira R, Takahashi RN, Da Cunha C (2002) Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 58:41-47
41. Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 137:120-123
42. Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681-683
43. Mura A, Feldon J (2003) Spatial learning in rats is impaired after degeneration of the nigrostriatal dopaminergic system. Mov Disord 18:860-871
44. Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K (2002) The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 23:1471-1478
45. Owen AM, Iddon JL, Hodges JR, Summers BA, Robbins TW (1997) Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia 35:519-532
46. Paccalin M, Pain-Barc S, Pluchon C, Paul C, Bazin H, Gil R, Hugon J (2005) The relation between p70S6k expression in lymphocytes and the decline of cognitive test scores in patients with Alzheimer disease. Arch Intern Med 165:2428-2429
47. Packard MG, McGaugh JL (1992) Double dissociation of fornix and caudate nucleus lesions on acquisition of two water maze tasks: further evidence for multiple memory systems. Behav Neurosci 106:439-446
48. Perry JC, Da Cunha C, Anselmo-Franci J, Andreatini R, Miyoshi E, Tufik S, Vital MA (2004) Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats. Eur J Pharmacol 484:225-233
49. Proud CG (1992) Protein phosphorylation in translational control. Curr Top Cell Regul 32:243-369
50. Raught B, Gingras AC, Sonenberg N (2001) The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 98:7037-7044
51. Reglodi D, Somogyvari-Vigh A, Vigh S, Maderdrut JL, Arimura A (2000) Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions. Ann NY Acad Sci 921:119-128
52. Reglodi D, Tamas A, Somogyvari-Vigh A, Szanto Z, Kertes E, Lenard L, Arimura A, Lengvari I (2002) Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 23:2227-2234
53. Reglodi D, Tamas A, Lubics A, Szalontay L, Lengvari I (2004a) Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Regul Pept 123:85-94
54. Reglodi D, Lubics A, Tamas A, Szalontay L, Lengvari I (2004b) Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav Brain Res 151:303-312
55. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA (2002) Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 22:10690-10698
56. Sawaguchi T (2000) The role of D1-dopamine receptors in working memory-guided movements mediated by frontal cortical areas. Parkinsonism Relat Disord 7:9-19
57. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215-224
58. Schultz W (1984) Recent physiological and pathophysiological aspects of Parkinsonian movement disorders. Life Sci 34:2213-2223
59. Setlow B, McGaugh JL (2000) D2 dopamine receptor blockade immediately post-training enhances retention in hidden and visible platform versions of the water maze. Learn Mem 7:187-191
60. Shen YQ, Hebert G, Lin LY, Luo YL, Moze E, Li KS, Neveu PJ (2005) Interleukin-1beta and interleukin-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. J Neuroimmunol 158:14-25
61. Stumm R, Kolodziej A, Prinz V, Endres M, Wu DF, Hollt V (2007) Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem 103:1666-1681
62. Takei N, Skoglosa Y, Lindholm D (1998) Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons. J Neurosci Res 54:698-706
63. Tamas A, Lubics A, Lengvari I, Reglodi D (2006) Protective effects of PACAP in excitotoxic striatal lesion. Ann NY Acad Sci 1070:570-574
64. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM (2002) A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 99:467-472
65. Tanila H, Bjorklund M, Riekkinen P Jr (1998) Cognitive changes in mice following moderate MPTP exposure. Brain Res Bull 45:577-582
66. Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048
67. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000a) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324
68. Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H (2000b) The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proc Natl Acad Sci USA 97:13390-13395
69. Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ (2003) Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 72:303-316
70. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98:2837-2842
71. Wang G, Qi C, Fan GH, Zhou HY, Chen SD (2005) PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS Lett 579:4005-4011
72. Wang G, Pan J, Tan YY, Sun XK, Zhang YF, Zhou HY, Ren RJ, Wang XJ, Chen SD (2008) Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum. Neuropeptides 42:267-276